Technoderma Medicines, a biopharmaceutical firm in the clinical stage, has initiated patient dosing in the Phase 2a segment of its clinical trial for the topical
TDM-180935 ointment, aimed at treating
Atopic Dermatitis (AD), commonly known as
eczema. The 8-week trial will compare two distinct active formulations against a placebo in an effort to preliminarily gauge the efficacy, safety, tolerability, and pharmacokinetics of the treatment. This randomized and vehicle-controlled study is being conducted across seven U.S. clinical sites and is registered with the FDA.
The company's Chief Medical Officer, Arthur P. Bertolino, has expressed optimism about the study's potential to establish the proof-of-concept for TDM-180935, particularly in terms of its efficacy and the selection of the most suitable formulation for further development. TDM-180935, a
JAK1/
Tyk2 small molecule inhibitor, is anticipated to provide significant benefits in both effectiveness and safety when compared to current treatments for
AD.
Zengquan Wang, CEO of Technoderma Medicines, has highlighted the successful Phase 1 development of TDM-180935, which showed excellent toleration and minimal systemic absorption. The company is now keen on evaluating its preliminary efficacy in treating AD and is committed to advancing its pipeline of products for dermatological conditions.
TDM-180935 is a promising drug candidate for AD, which has shown efficacy in various models and is deemed suitable for topical application. It has the potential to suppress pathogenic pathways associated with AD, as demonstrated through functional cell assays. Toxicology and toxicokinetic studies in rats and minipigs have yielded positive results, and Phase 1 clinical trials have confirmed the ointment's safety with minimal absorption into the body.
AD is a prevalent chronic
skin condition characterized by
inflammation,
itching, and dryness, affecting various parts of the body. Its prevalence is on the rise, particularly in children and adults in industrialized nations. The condition's development is linked to genetic factors and family history of atopic diseases.
Technoderma Medicines, based in Chengdu Tianfu BioPark, is dedicated to developing innovative treatments for various dermatological conditions, including
Androgenetic Alopecia,
Psoriasis, and
Lupus Erythematosus. The company's pipeline is focused on dermatologic indications, with its "first-in-class" thyromimetic drug candidate,
TDM-105795, having successfully completed Phase 2a clinical testing and is progressing further.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
